In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantation - PubMed

In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantation

S C Gulati et al. Cancer Invest. 1989.

Abstract

Intensive chemotherapy requiring rescue with autologous bone marrow may be an encouraging mode of treatment for poor prognosis Ewing's sarcoma (ES). In vitro chemosensitivity test may be useful for establishing an effective purging condition. We studied the in vitro effects of a variety of chemotherapeutic agents on two established ES cell lines (ES-5838 and ES-A4573) and marrow colony-forming unit-granulocyte macrophage (CFU-GM). 4-Hydroperoxycyclophosphamide (4-HC), at 100 microM produced complete inhibition (greater than 5 log) of clonogenic growth of both ES cell lines and spared 6.9% of normal CFU-GM growth. Etoposide (VP-16), at 100 microM produced 3-3.5 log inhibition of ES cell lines and complete inhibition of CFU-GM growth. Adriamycin (ADR) and vincristine (VCR) were more cytotoxic to ES-5838 cells than ES-A4573 cells. ADR at 1 microM produced 99.7% inhibition of ES-5838 cells, 92.2% of ES-A4573 cells, and 86% inhibition of CFU-GM. VCR at 1 microM produced 98.6% inhibition of ES-5838 cells, only 43.7% of ES-A4573 cells, and 75% inhibition of CFU-GM growth. Addition of verapamil did not enhance VCR cytotoxicity of ES cell lines. These studies indicate that 4-HC may be a useful agent for purging metastatic ES cells from the bone marrow for autologous marrow transplantation.

Similar articles

• In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide.

  Gulati SC, Kwon JH, Kushner B, Cheung NK, Atzpodien J, Shum K, Clarkson BD. Gulati SC, et al. Cancer Invest. 1989;7(5):417-22. doi: 10.3109/07357908909041372. Cancer Invest. 1989. PMID: 2515915

• Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.

  Carlo-Stella C, Mangoni L, Almici C, Garau D, Craviotto L, Piovani G, Caramatti C, Rizzoli V. Carlo-Stella C, et al. Exp Hematol. 1992 Mar;20(3):328-33. Exp Hematol. 1992. PMID: 1568448

• Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.

  Rowley SD, Jones RJ, Piantadosi S, Braine HG, Colvin OM, Davis J, Saral R, Sharkis S, Wingard J, Yeager AM, et al. Rowley SD, et al. Blood. 1989 Jul;74(1):501-6. Blood. 1989. PMID: 2665843

• In vitro evaluation of combination drug purging for autologous bone marrow transplantation.

  Jones RJ, Miller CB, Zehnbauer BA, Rowley SD, Colvin OM, Sensenbrenner LL. Jones RJ, et al. Bone Marrow Transplant. 1990 May;5(5):301-7. Bone Marrow Transplant. 1990. PMID: 2350626

Cited by

• Sarcoma stem cells: do we know what we are looking for?

  Trucco M, Loeb D. Trucco M, et al. Sarcoma. 2012;2012:291705. doi: 10.1155/2012/291705. Epub 2012 May 9. Sarcoma. 2012. PMID: 22654552 Free PMC article.

• High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

  Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM. Awad O, et al. PLoS One. 2010 Nov 11;5(11):e13943. doi: 10.1371/journal.pone.0013943. PLoS One. 2010. PMID: 21085683 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information

• Research Materials

  • Cellosaurus - a cell line knowledge resource
  • NCI CPTC Antibody Characterization Program